CytoSorbents New Logo - 2021.png
Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
March 29, 2023 08:30 ET | CytoSorbents
PRINCETON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents ISICEM 2023 Picture
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
March 22, 2023 08:09 ET | CytoSorbents
PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
mrf.jpg
Sepsis Diagnostics Market Size to Surpass USD 1582.23 Million by 2030 at 9.80% CAGR – Report by Market Research Future (MRFR)
February 02, 2023 09:00 ET | Market Research Future
New York, USA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sepsis Diagnostics Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Sepsis Diagnostics Market...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
January 26, 2023 14:05 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases
January 06, 2023 14:50 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
logo.png
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
January 04, 2023 08:00 ET | Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
22157.jpg
Global AI and Trust in Healthcare Research Report 2022: Validation of Models, Explainability and Transparency, & Data Ethics and AI
November 23, 2022 06:38 ET | Research and Markets
Dublin, Nov. 23, 2022 (GLOBE NEWSWIRE) -- The "2022 AI and Trust in Healthcare Report" report has been added to ResearchAndMarkets.com's offering. The"AI and Trust in Healthcare"report examines...
TIP_link_300x300.jpg
Sepsis Diagnostics Market Worth $1,226.52 Million, Globally, by 2028 at 9.2% CAGR - Exclusive Report by The Insight Partners
May 13, 2022 09:32 ET | The Insight Partners
New York, May 13, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product...
Press release Biocar
Press release Biocartis Group NV: SeptiCyte® RAPID Receives 510(k) clearance by US FDA
November 30, 2021 11:40 ET | Biocartis NV
PRESS RELEASE: 30 November 2021, 17:40 CET SeptiCyte® RAPID Receives 510(k) clearance by US FDA Mechelen, Belgium, 30 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an...
Persbericht Biocarti
Persbericht Biocartis Group NV: SeptiCyte® RAPID krijgt 510(k) clearance van de US FDA
November 30, 2021 11:40 ET | Biocartis NV
PERSBERICHT: 30 november 2021, 17:40 CET SeptiCyte® RAPID krijgt 510(k) clearance van de US FDA Mechelen, België, 30 november 2021 – Biocartis Group NV (de ‘Vennootschap’ of ‘Biocartis’), een...